Assays & Kits

The HSP90α Assay Kit is designed for identification of HSP90α inhibitors using fluorescence polarization. The assay is based on the competition of fluorescently labeled geldanamycin for binding to purified recombinant HSP90α. The key to the HSP90α Assay Kit is the fluorescently labeled geldanamycin. Using this kit, only one simple step on a microtiter plate is required for HSP90α reactions. The fluorescently labeled geldanamycin is incubated with a sample containing HSP90α enzyme to produce a change in fluorescent polarization. The FP signal is measured using a fluorescent microplate reader capable of measuring fluorescence polarization.

The HSP90β Assay Kit is designed for identification of HSP90β inhibitors using fluorescence polarization. The assay is based on the competition of fluorescently labeled geldanamycin for binding to purified recombinant HSP90β. The key to the HSP90β Assay Kit is the fluorescently labeled geldanamycin. Using this kit, only one simple step on a microtiter plate is required for HSP90β reactions. The fluorescently labeled geldanamycin is incubated with a sample containing HSP90β enzyme to produce a change in fluorescent polarization. The FP signal is measured using a fluorescent microplate reader capable of measuring fluorescence polarization.

The HSP90α (N-terminal) Assay Kit is designed for identification of HSP90α inhibitors using fluorescence polarization. The assay is based on the competition of fluorescently labeled geldanamycin for binding to purified recombinant HSP90α. The key to the HSP90α Assay Kit is the fluorescently labeled geldanamycin. Using this kit, only one simple step on a microtiter plate is required for HSP90α reactions. The fluorescently labeled geldanamycin is incubated with a sample containing HSP90α enzyme to produce a change in fluorescent polarization. The FP signal is measured using a fluorescent microplate reader capable of measuring fluorescence polarization.

The HSP90β (N-terminal) Assay Kit is designed for identification of HSP90β inhibitors using fluorescence polarization. The assay is based on the competition of fluorescently labeled geldanamycin for binding to purified recombinant HSP90β. The key to the HSP90β Assay Kit is the fluorescently labeled geldanamycin. Using this kit, only one simple step on a microtiter plate is required for HSP90β reactions. The fluorescently labeled geldanamycin is incubated with a sample containing HSP90β enzyme to produce a change in fluorescent polarization. The FP signal is measured using a fluorescent microplate reader capable of measuring fluorescence polarization.

The HSP90β (C-terminal) Inhibitor Screening Assay Kit is designed to measure the inhibition of HSP90β binding to its protein target PPID (also known as Cyclophilin D). With this kit, only three simple steps on a microtiter plate are required. First, a sample containing HSP90β, PPID, and an inhibitor of choice is incubated for thirty minutes. Next, acceptor beads are added, then donor beads, followed by reading the Alpha-counts.

The HSP90α (C-Terminal) Inhibitor Screening Assay Kit is designed to measure the inhibition of HSP90α binding to its protein target PPID (also known as Cyclophilin D). With this kit, only three simple steps on a microtiter plate are required. First, a sample containing HSP90α, PPID, and an inhibitor of choice is incubated for thirty minutes. Next, acceptor beads are added, then donor beads, followed by reading the Alpha-counts.

Histone H3 peptide (a.a. 1-21), tri-methylated at Lysine 9 with a C-terminal GG linker followed by a biotinylated Lys at its C-terminus.

Histone H3 peptide (a.a. 1-21), di-methylated at Lysine 9 with a C-terminal GG linker followed by a biotinylated Lys at its C-terminus.

Histone peptide substrate for PRMT4 (CARM1), biotinylated at its C-terminus.